Could AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) Go Down After Its Newest Short Interest Report?

November 14, 2017 - By Ellis Scott

The stock of AMARANTUS BIOSCIENCE HOLDINGS IN (OTCMKTS:AMBS) registered a decrease of 96% in short interest. AMBS’s total short interest was 100 shares in November as published by FINRA. Its down 96% from 2,500 shares, reported previously.

About 254,132 shares traded or 99.36% up from the average. Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) has 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical holding company. The company has market cap of $1.61 million. The Firm has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. It currently has negative earnings. It owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry.

More notable recent Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) news were published by: Prnewswire.com which released: “Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience …” on November 19, 2014, also Marketwatch.com with their article: “0.0212” published on June 30, 2011, Seekingalpha.com published: “Amarantus’ LymPro Could Be A Game-Changer For Alzheimer’s Diagnosis” on April 17, 2013. More interesting news about Amarantus Bioscience Holdings Inc (OTCMKTS:AMBS) were released by: Globenewswire.com and their article: “Amarantus Effects Capital Restructuring in Anticipation of National Exchange …” published on May 22, 2015 as well as Usmarketsdaily.com‘s news article titled: “AMARANTUS BIOSCIENCE HOLDINGS, INC. (OTCBB:AMBS) Pays $2.3 Million In Final …” with publication date: March 06, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.